Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study

Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection

(2015) Jerome H. Kim et al.   Annual Review of Medicine

Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates

(2015) Xiaoying Shen et al.   JOURNAL OF VIROLOGY

Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies

(2015) W. B. Williams et al.   SCIENCE

Polymeric penetration enhancers promote humoral immune responses to mucosal vaccines

(2014) Katja Klein et al.   JOURNAL OF CONTROLLED RELEASE

Effect of Vaginal Immunization with HIVgp140 and HSP70 on HIV-1 Replication and Innate and T Cell Adaptive Immunity in Women

(2014) D. J. M. Lewis et al.   JOURNAL OF VIROLOGY

HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities

(2014) Justin Pollara et al.   JOURNAL OF VIROLOGY

GLA-AF, an Emulsion-Free Vaccine Adjuvant for Pandemic Influenza

(2014) Christopher H. Clegg et al.   PLoS One

Mixture models for single-cell assays with applications to vaccine studies

(2013) G. Finak et al.   BIOSTATISTICS

Epitope Specificity of Human Immunodeficiency Virus-1 Antibody Dependent Cellular Cytotoxicity [ADCC] Responses

(2013) Justin Pollara et al.   CURRENT HIV RESEARCH

Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1

(2013) Marcella Sarzotti-Kelsoe et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Neutralizing IgG at the Portal of Infection Mediates Protection against Vaginal Simian/Human Immunodeficiency Virus Challenge

(2013) K. Klein et al.   JOURNAL OF VIROLOGY

Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques

(2013) C Moog et al.   Mucosal Immunology

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial

(2013) Raphael Gottardo et al.   PLoS One

Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation

(2013) R. P. Ringe et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

(2013) G. D. Tomaras et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination

(2013) Mirte Scherpenisse et al.   Human Vaccines & Immunotherapeutics

Glycan profiles of the 27 N-glycosylation sites of the HIV envelope protein CN54gp140

(2012) Martin Pabst et al.   BIOLOGICAL CHEMISTRY

Optimization and qualification of a multiplex bead array to assess cytokine and chemokine production by vaccine-specific cells

(2012) Olivier D. Defawe et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study)

(2012) A. Duerr et al.   JOURNAL OF INFECTIOUS DISEASES

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140

(2012) Mauricio A. Arias et al.   PLoS One

Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice

(2012) Viviana Buffa et al.   PLoS One

A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines

(2012) John T. Schiller et al.   VACCINE

Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine

(2011) Tino F. Schwarz et al.   Human vaccines & immunotherapeutics

Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated

(2011) Hua-Xin Liao et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Phase I Randomised Clinical Trial of an HIV-1CN54, Clade C, Trimeric Envelope Vaccine Candidate Delivered Vaginally

(2011) David J. Lewis et al.   PLoS One

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

(2011) D. R. Burton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adjuvanted Intranasal Norwalk Virus‐Like Particle Vaccine Elicits Antibodies and Antibody‐Secreting Cells That Express Homing Receptors for Mucosal and Peripheral Lymphoid Tissues

(2010) Samer S. El‐Kamary et al.   JOURNAL OF INFECTIOUS DISEASES

Antibody responses after intravaginal immunisation with trimeric HIV-1CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation

(2010) Martin P. Cranage et al.   VACCINE

First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants

(2009) Julia L Hurwitz et al.   AIDS

Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses

(2009) M P Cranage et al.   Mucosal Immunology